Recent studies underscore the need for prompt diagnosis and differentiation between AL and ATTR, as specific therapies—ranging from chemotherapeutic agents to transthyretin stabilizers and gene silencers—are now available, making early identification imperative [21,22]. The gene discussed is TTR; the disease is axial length measurement.